Phathom Pharmaceuticals, Inc.: Invesco Ltd. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Invesco Ltd. amended its Schedule 13G filing for Phathom Pharmaceuticals, Inc., updating its beneficial ownership stake with the SEC under accession number 0000914208-26-000448. The filing, submitted under Invesco's CIK 0000914208, revises the institutional investor's previously reported position in the specialty pharmaceutical company. Schedule 13G amendments are required when a passive investor's ownership crosses certain thresholds or materially changes, making the update a signal of shifting institutional interest in Phathom. Investors will watch for the specific share count and percentage disclosed in the amendment to gauge whether Invesco increased, trimmed or maintained its exposure. Further details on Phathom's ownership composition may emerge as other institutional holders update their filings.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Phathom Pharmaceuticals, Inc., Invesco Ltd.